Tuesday May 5, 2026
This week’s digest is a day late — and we’ll own it. But blame J&J. The first clinical data for J&J and the OTTAVA robotic surgical system dropped this morning, and we wanted it in your hands before we shipped. It was a big story worth waiting on.
The theme this week is competition — in the OR, in the EP lab, and in the supply chain. Robotics is heating up on multiple fronts, the AThe fib ablation market is fragmenting fast, and the US-China tariff truce is giving device manufacturers a window to reset their strategy. Here’s what matters this week.
8 things to watch this week:
1. 🤖 J&J Releases First Clinical Data for OTTAVA Robotic System, Files for FDA De Novo Clearance
Johnson & Johnson today presented first-in-human clinical results from its OTTAVA robotic surgical system at the ASMBS Annual Meeting in San Antonio. In a 30-patient multicenter cohort evaluating Roux-en-Y gastric bypass, the system met all primary safety and performance endpoints through 30 days post-procedure — and was successfully deployed in ORs as small as 243 sq. ft., including rooms never previously used for robotic surgery. J&J simultaneously filed a De Novo classification request with FDA targeting multiple upper abdominal procedures. With da Vinci’s dominance long unchallenged in soft tissue, a credible competitor just got a lot more credible.
Business Wire / Yahoo Finance
2. 🎯 Most medical device companies don’t fail on technology. They fail on sequencing.
The most expensive mistakes in Class II and III device commercialization aren’t made in the field. They’re made before it — launching before buyer clarity exists, fundraising before the story holds up, hiring before positioning is right.
The CLIF Analysis (Commercial Launch Impact Framework) from RŌG Health is a fast, structured external diagnostic designed to surface those gaps before they become costly. One week. Built for medical device and medtech teams.
Sponsored
3. 🌐 US-China Tariff Truce Gives MedTech Manufacturers Room to Breathe — For Now
The US and China reached a partial trade agreement in early May, rolling back tariffs on a broad range of industrial goods, including medical device components — sensors, precision instruments, plastics, and metals that had faced duties as high as 145% at peak. For medtech startups and scale-ups in particular, the deal provides a more predictable cost environment. But the clock is running: it’s a 90-day pause, USTR Section 301 public hearings on broader manufacturing tariffs are scheduled this week, and AdvaMed CEO Scott Whitaker is still pressing for a permanent “zero for zero” reciprocal tariff policy. Relief is real. Permanence is not.
BIOMEDevice Boston / MedDeviceGuide
4.💓 HRS 2026: Pulse Biosciences’ Nanosecond PFA Data Turns Heads in Electrophysiology
At Heart Rhythm Society 2026 in Chicago last week, Pulse Biosciences presented updated data from its nPulse Cardiac Catheter first-in-human European feasibility study: 100% procedural success at 6 months (95/95 patients), 96% at 12 months (51/53), and 90% Kaplan-Meier freedom from atrial arrhythmias at one year — with a total procedure time averaging just over 60 minutes. The company also confirmed it has commenced enrollment in its US IDE pivotal trial, with completion now targeted for early Q4 2026. In a PFA market currently dominated by Medtronic, Boston Scientific, and Abbott, the nanosecond PFA approach is generating genuine attention as a potential next-generation differentiator.
Pulse Biosciences IR / BioSpace
5. ⚡ HRS 2026: Abbott and Boston Scientific Both Stake Their PFA Ground in a Crowded EP Market
Also at HRS 2026, Abbott presented six-month IDE data for its TactiFlex Duo Ablation Catheter, showing positive outcomes in complex AFib cases, as well as first-in-human data for its investigational AVEIR CSP leadless pacemaker system. Boston Scientific countered with positive data from the Farapulse PFA and Watchman LAAC. With Medtronic’s PulseSelect, Abbott, BSX, Kardium, and now Pulse Biosciences all competing in the pulsed field ablation space, HRS 2026 underscored how rapidly this market is fragmenting — and provides useful context for Boston Scientific’s surprising guidance cut the week prior.
Abbott / Boston Scientific via PR Newswire / MDDI
6. 💤 SleepRes Wins FDA 510(k) Clearance for Adaptive PAP Device Targeting CPAP’s Adherence Problem
SleepRes received FDA 510(k) clearance this week for its Kricket PAP device, which uses Kairos technology to dynamically adjust pressure throughout the breathing cycle — in contrast to traditional fixed-pressure CPAP. The device is cleared for home, hospital, and sleep center use in patients over 66 lbs, with commercial launch planned for H1 2026. CPAP adherence remains one of sleep medicine’s most persistent unsolved problems, and adaptive pressure technology represents a meaningful clinical differentiation play in a large, underpenetrated market.
Medical Economics
7. ⚠️ U.S. Hospital Dependence on Chinese-Manufactured Devices Poses Security Risk, Expert Warns
A medical device security expert flagged in a May 4 MDDI report that US hospital dependence on Chinese-manufactured devices presents supply chain security vulnerabilities that extend beyond cost, raising concerns about geopolitical exposure in critical care settings. The issue is particularly acute for imaging systems, monitoring equipment, and disposables, where Chinese manufacturing share remains significant. The warning lands in the same week as USTR Section 301 hearings and is a reminder that the tariff conversation has dimensions that go beyond input costs.
MDDI
8. 🏛️ FDA Announces Major Steps to Implement Real-Time Clinical Trials
On April 28, the FDA announced concrete steps toward implementing real-time clinical trial infrastructure — a framework designed to accelerate the generation, review, and action on evidence for medical devices and combination products. This initiative follows the RAPID coverage pathway announcement the prior week and reflects the current administration's ongoing effort to compress approval and coverage timelines. For device companies now designing pivotal trials, the signal is worth building into their protocol and evidence-generation strategy.
FDA.gov
Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.